Amid controversy over drugs like Ozempic and Mounjaro, India’s drug regulator has stepped up action against unauthorised sale and promotion of GLP-1 based weight loss medicines. The Ministry of Health and Family Welfare said on Tuesday that regulatory surveillance has been intensified to ensure ethical practices across the pharmaceutical supply chain.
The move comes after the entry of several generic versions of GLP-1 drugs in the Indian market. Officials flagged concerns that these medicines are being made available on demand through retail pharmacies, online platforms, wholesalers and wellness clinics.
The ministry warned that use without proper medical supervision could lead to serious side effects and health risks.
On March 10, 2026, the Drugs Controller issued a detailed advisory to manufacturers. It clearly banned surrogate advertising and any indirect promotion that could mislead consumers or encourage off-label use.
In recent weeks, enforcement has been scaled up with inspections carried out at 49 entities. These included online pharmacy warehouses, wholesalers, retailers and wellness or slimming clinics across different parts of the country. The checks focused on identifying violations such as unauthorised sales, improper prescription practices and misleading marketing. Notices have been issued to those found in violation.
The regulator said patient safety remains the top priority and warned that misuse of such drugs without clinical supervision can cause severe health complications. It reiterated that these medicines are approved in India only with prescriptions from endocrinologists and internal medicine specialists, and for certain uses by cardiologists.
Authorities said monitoring will continue to be intensified in the coming weeks. Non-compliance could lead to strict action, including cancellation of licences, penalties and prosecution under existing laws, the Health Ministry added.
